Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 135

Sort by

Sort Order Select

Journal Articles

GSDME-mediated Pyroptosis Contributes to Chemotherapy-induced Platelet Hyperactivity and Thrombotic Potential

Ruyi Xue, Min Li, Ge Zhang, Wei Zhang, Liping Han, Tao Bo, Haoxuan Zhong, Dingjin Yao, Yiran Deng, She Chen, Si Zhang

Blood blood.2023023179.

https://doi.org/10.1182/blood.2023023179

Published: 2024

Includes: Supplemental data

Journal Articles

Development of a Same-Day Closed CAR-T Cell Manufacturing Process to Generate Lentivector Loaded Lymphocytes Ready for Subcutaneous Injection

Sid Kerkar, Lintao Liu, Michael Betts, Liang Li, Michelle Andraza, Ewa Jaruga-Killeen, Cody Gowan, Ting Han, Jia Shi, Rang Gao, Suraj Kachgal, Gregory Wade, Wei Zhang, Gregory Frost

Blood (2023) 142 (Supplement 1): 6812.

https://doi.org/10.1182/blood-2023-189117

Published: 2023

Journal Articles

Treatment Pattern and Survival of Human Immunodeficiency Virus Infection-Related Lymphoma in China 2008-2021

Jun Liu, Chaoyu Wang, Tao Yang, Yan Wu, Haiyan Min, Yunhong Huang, Guo Wei, Wei Zhang, Min Wang, Xiaoqiong Tang, Hui Zhou, Yao Liu

Blood (2023) 142 (Supplement 1): 6299.

https://doi.org/10.1182/blood-2023-182535

Published: 2023

Journal Articles

Clinical Analysis of 22 Cases of HIV-Associated Hodgkin Lymphoma in China

Chaoyu Wang, Jun Liu, Yan Wu, Haiyan Min, Tao Yang, Wei Zhang, Hui Zhou, Yao Liu

Blood (2023) 142 (Supplement 1): 6293.

https://doi.org/10.1182/blood-2023-180572

Published: 2023

Journal Articles

Humanized Monoclonal Antibody IMM47, Targeting CD24, Exhibits Exceptional Anti-Tumor Efficacy By Blocking the CD24/Siglec-10 Interaction and Can be Used As Monotherapy or in Combination with Anti-PD1 Antibodies for Cancer Immunotherapy

Jifeng Yu, Song Li, Dianze Chen, Huiqin Guo, Yanan Yang, Dandan Liu, Chunmei Yang, Xing Bai, Wei Zhang, Li Zhang, Gui Zhao, Xiaoping Tu, Liang Peng, Sijin Liu, Yongping Song, Zhongxing Jiang, Ruliang Zhang, Wenzhi Tian

Blood (2023) 142 (Supplement 1): 7140.

https://doi.org/10.1182/blood-2023-172483

Published: 2023

Journal Articles

Subgroup Analysis from a Phase 2, Single-Arm Trial of the Oral PI3Kδ Inhibitor Linperlisib in Patients with Relapsed or Refractory Follicular Lymphoma

Blood (2023) 142 (Supplement 1): 6145.

https://doi.org/10.1182/blood-2023-177820

Published: 2023

Journal Articles

Development and Validation of a Machine-Learning Model to Predict POD24 Risk of Follicular Lymphoma

Blood (2023) 142 (Supplement 1): 3048.

https://doi.org/10.1182/blood-2023-182812

Published: 2023

Journal Articles

Results of a Second, Prespecified Analysis of the Phase 2 Study ELM-2 Confirm High Rates of Durable Complete Response with Odronextamab in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) with Extended Follow-up

Blood (2023) 142 (Supplement 1): 3041.

https://doi.org/10.1182/blood-2023-181650

Published: 2023

Journal Articles

Maintenance of Moderate to High Levels of Functioning and Quality of Life with Odronextamab Monotherapy in Patients with Relapsed or Refractory Follicular Lymphoma

Blood (2023) 142 (Supplement 1): 669.

https://doi.org/10.1182/blood-2023-181942

Published: 2023

Journal Articles

A Prognostic Nomogram Survival Model for Newly Diagnosed Patients with AIDS-Related Diffuse Large B-Cell Lymphoma: A Multicenter Cohort Study in China

Tao Yang, Yang Liang, Chaoyu Wang, Jun Liu, Yan Wu, Haiyan Min, Yunhong Huang, Guo Wei, Wei Zhang, Min Wang, Xiaoqiong Tang, Zailin Yang, Li Jun, Hui Zhou, Yao Liu

Blood (2023) 142 (Supplement 1): 4480.

https://doi.org/10.1182/blood-2023-179132

Published: 2023

Journal Articles

Efficacy, Safety, and Population Pharmacokinetics of Eltrombopag in Children with Different Severities of Aplastic Anemia

Wei Zhang, Li-xian Chang, Bei-bei Zhao, Dan-dan Shan, Bo-hao Tang, Fan Yang, Yue Zhou, Guo-xiang Hao, Yi Zheng, Ya-hui Zhang, John Van Den Anker, Xiaofan Zhu, Li Zhang, Wei Zhao

Blood (2023) 142 (Supplement 1): 1345.

https://doi.org/10.1182/blood-2023-181581

Published: 2023

Journal Articles

Time to Lymphoma Treatment within 24 Months in Watchful Waiting Follicular Lymphoma Defines Patients at High Risk for Progression: A Multicenter Analysis

Fenghua Gao, Jing Liu, Jiesong Wang, Lihong Liu, Zhiming Li, Yuqin Song, Xudong Zhang, Hui Zhou, Xiuhua Sun, Wei Zhang, Bing Xu, Liping Su, Wen Shujuan, Rong Tao, Ou Bai, Qingyuan Zhang, Liqun Zou, Xianhuo Wang, Huilai Zhang

Blood (2023) 142 (Supplement 1): 4417.

https://doi.org/10.1182/blood-2023-174308

Published: 2023

Journal Articles

PI3Kδ Inhibitor Linperlisib As a ≥ 3-Line Treatment for Relapsed or Refractory Follicular Lymphoma: A Subgroup Analysis of a Phase II, Single-Arm, Open-Label Trial

Blood (2023) 142 (Supplement 1): 1677.

https://doi.org/10.1182/blood-2023-178710

Published: 2023

Journal Articles

Extrachromosomal Circular DNA Drives the Progression of DLBCL through Activating the Sting Pathway

Zijuan Wu, Wei Zhang, Luqiao Wang, Lei Fan, Jianyong Li, Hui Jin

Blood (2023) 142 (Supplement 1): 1628.

https://doi.org/10.1182/blood-2023-190771

Published: 2023

Journal Articles

Analysis of Influencing Factors of Positive Antiplatelet Antibody in Patients with Diffuse Large B-Cell Lymphoma

Wei Zhang, Longrong Ran, Mingyu Zhao, Yu Peng, Xin Luo, Shuang Chen, Zailin Yang, Yao Liu

Blood (2023) 142 (Supplement 1): 6300.

https://doi.org/10.1182/blood-2023-182666

Published: 2023

Journal Articles

Dose Adjustments of Linperlisib in Relapsed or Refractory Follicular Lymphoma: A Post-Hoc Analysis of a Pivotal Phase II Study

Blood (2023) 142 (Supplement 1): 6140.

https://doi.org/10.1182/blood-2023-180373

Published: 2023

Journal Articles

A novel RIPK1 inhibitor reduces GVHD in mice via a nonimmunosuppressive mechanism that restores intestinal homeostasis

Blood (2023) 141 (9): 1070–1086.

https://doi.org/10.1182/blood.2022017262

Published: 2023

Includes: Supplemental data

Journal Articles

Analysis of Fluorescence in Situ Hybridization Detection Results and Clinical Indicators in 51 Patients with Multiple Myeloma

Mingyu Zhao, Longrong Ran, Xin Luo, Lian Li, Yu Peng, Shuang Chen, Wei Zhang, Zailin Yang

Blood (2022) 140 (Supplement 1): 12551.

https://doi.org/10.1182/blood-2022-166581

Published: 2022

Journal Articles

Novel Sirpα-Fc Fusion Protein IMM01 Exhibits Dual Anti-Tumor Activities By Targeting CD47/Sirpα Signal Pathway

Jifeng Yu, Song Li, Dianze Chen, Dandan Liu, Huiqin Guo, Chunmei Yang, Wei Zhang, Li Zhang, Gui Zhao, Xiaoping Tu, Liang Peng, Sijin Liu, Xing Bai, Yongping Song, Zhongxing Jiang, Ruliang Zhang, Wenzhi Tian

Blood (2022) 140 (Supplement 1): 3067–3068.

https://doi.org/10.1182/blood-2022-155977

Published: 2022

Journal Articles

Genetic and Prognostic Analysis in Blastoid and Pleomorphic Mantle Cell Lymphoma: A Multicenter Analysis in China

Ping Yang, Shuozi Liu, Chunyuan Li, Weilong Zhang, Jing Wang, Yingtong Chen, Sen Li, Cuiling Liu, Hui Liu, Qingqing Cai, Wei Zhang, Hongmei Jing

Blood (2022) 140 (Supplement 1): 11907–11908.

https://doi.org/10.1182/blood-2022-165107

Published: 2022

NARROW

GSDME-mediated Pyroptosis Contributes to Chemotherapy-induced Platelet Hyperactivity and Thrombotic Potential

Development of a Same-Day Closed CAR-T Cell Manufacturing Process to Generate Lentivector Loaded Lymphocytes Ready for Subcutaneous Injection

Treatment Pattern and Survival of Human Immunodeficiency Virus Infection-Related Lymphoma in China 2008-2021

Clinical Analysis of 22 Cases of HIV-Associated Hodgkin Lymphoma in China

Humanized Monoclonal Antibody IMM47, Targeting CD24, Exhibits Exceptional Anti-Tumor Efficacy By Blocking the CD24/Siglec-10 Interaction and Can be Used As Monotherapy or in Combination with Anti-PD1 Antibodies for Cancer Immunotherapy

Subgroup Analysis from a Phase 2, Single-Arm Trial of the Oral PI3Kδ Inhibitor Linperlisib in Patients with Relapsed or Refractory Follicular Lymphoma

Development and Validation of a Machine-Learning Model to Predict POD24 Risk of Follicular Lymphoma

Results of a Second, Prespecified Analysis of the Phase 2 Study ELM-2 Confirm High Rates of Durable Complete Response with Odronextamab in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) with Extended Follow-up

Maintenance of Moderate to High Levels of Functioning and Quality of Life with Odronextamab Monotherapy in Patients with Relapsed or Refractory Follicular Lymphoma

A Prognostic Nomogram Survival Model for Newly Diagnosed Patients with AIDS-Related Diffuse Large B-Cell Lymphoma: A Multicenter Cohort Study in China

Efficacy, Safety, and Population Pharmacokinetics of Eltrombopag in Children with Different Severities of Aplastic Anemia

Time to Lymphoma Treatment within 24 Months in Watchful Waiting Follicular Lymphoma Defines Patients at High Risk for Progression: A Multicenter Analysis

PI3Kδ Inhibitor Linperlisib As a ≥ 3-Line Treatment for Relapsed or Refractory Follicular Lymphoma: A Subgroup Analysis of a Phase II, Single-Arm, Open-Label Trial

Extrachromosomal Circular DNA Drives the Progression of DLBCL through Activating the Sting Pathway

Analysis of Influencing Factors of Positive Antiplatelet Antibody in Patients with Diffuse Large B-Cell Lymphoma

Dose Adjustments of Linperlisib in Relapsed or Refractory Follicular Lymphoma: A Post-Hoc Analysis of a Pivotal Phase II Study

A novel RIPK1 inhibitor reduces GVHD in mice via a nonimmunosuppressive mechanism that restores intestinal homeostasis

Analysis of Fluorescence in Situ Hybridization Detection Results and Clinical Indicators in 51 Patients with Multiple Myeloma

Novel Sirpα-Fc Fusion Protein IMM01 Exhibits Dual Anti-Tumor Activities By Targeting CD47/Sirpα Signal Pathway

Genetic and Prognostic Analysis in Blastoid and Pleomorphic Mantle Cell Lymphoma: A Multicenter Analysis in China

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only